On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
A key update confirms ARQ 531 as the leading contender to treat patients who relapse on Imbruvica or Calquence.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
A slew of data on spinal muscular atrophy projects over the weekend shows that this tiny market is set for some big competition, with Novartis, Roche and Biogen jostling…
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.